Drug Profile
EDD 7H9
Alternative Names: 7H9; EDD-7H9Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Expression Drug Designs
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Sphingosine-1-phosphate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Sepsis
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
- 05 Sep 2023 Discontinued - Preclinical for Sepsis in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Breast-cancer in USA